BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 20331734)

  • 1. Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates.
    Patnaik MM; Knudson RA; Gangat N; Hanson CA; Pardanani A; Tefferi A; Ketterling RP
    Eur J Haematol; 2010 Jun; 84(6):518-24. PubMed ID: 20331734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms.
    Najfeld V; Cozza A; Berkofsy-Fessler W; Prchal J; Scalise A
    Exp Hematol; 2007 Nov; 35(11):1668-76. PubMed ID: 17976519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A der(18)t(9;18)(p13;p11) and a der(9;18)(p10;q10) in polycythemia vera associated with a hyperproliferative phenotype in transformation to postpolycythemic myelofibrosis.
    Larsen TS; Hasselbalch HC; Pallisgaard N; Kerndrup GB
    Cancer Genet Cytogenet; 2007 Jan; 172(2):107-12. PubMed ID: 17213018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A quantitative assay for JAK2 mutation in 135 patients with chronic myeloproliferative neoplasms].
    Chao HY; Shen YM; Zhang R; Feng YF; Cen JN; Yao L; Shen HJ; Zhu ZL; Xue YQ
    Zhonghua Xue Ye Xue Za Zhi; 2009 May; 30(5):321-5. PubMed ID: 19799128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of JAK2 mutation status and cytogenetic abnormalities in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.
    Dunlap J; Kelemen K; Leeborg N; Braziel R; Olson S; Press R; Huang J; Gatter K; Loriaux M; Fan G
    Am J Clin Pathol; 2011 May; 135(5):709-19. PubMed ID: 21502425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polycythemia vera transforming to acute myeloid leukemia and complex abnormalities including 9p homogeneously staining region with amplification of MLLT3, JMJD2C, JAK2, and SMARCA2.
    Hélias C; Struski S; Gervais C; Leymarie V; Mauvieux L; Herbrecht R; Lessard M
    Cancer Genet Cytogenet; 2008 Jan; 180(1):51-5. PubMed ID: 18068534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms.
    Smith CA; Fan G
    Hum Pathol; 2008 Jun; 39(6):795-810. PubMed ID: 18538168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic idiopathic myelofibrosis (CIMF) resulting from a unique 3;9 translocation disrupting the janus kinase 2 (JAK2) gene.
    Mark HF; Sotomayor EA; Nelson M; Chaves F; Sanger WG; Kaleem Z; Caughron SK
    Exp Mol Pathol; 2006 Dec; 81(3):217-23. PubMed ID: 16959246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromosome 8p11.2 translocations: prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution.
    Patnaik MM; Gangat N; Knudson RA; Keefe JG; Hanson CA; Pardanani A; Ketterling RP; Tefferi A
    Am J Hematol; 2010 Apr; 85(4):238-42. PubMed ID: 20143402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
    Chao HY; Fan Z; Zhang R; Shen YM; Chen W; Fei HR; Zhu ZL; Feng YF; Chen ZX; Xue YQ
    Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel t(1;9)(p36;p24.1) JAK2 Translocation and Review of the Literature.
    Levavi H; Tripodi J; Marcellino B; Mascarenhas J; Jones AV; Cross NCP; Gruenstein D; Najfeld V
    Acta Haematol; 2019; 142(2):105-112. PubMed ID: 31063994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCR-JAK2 fusion in a myeloproliferative neoplasm with associated eosinophilia.
    He R; Greipp PT; Rangan A; Mai M; Chen D; Reichard KK; Nelsen LL; Pardanani A; Hanson CA; Viswanatha DS
    Cancer Genet; 2016 May; 209(5):223-8. PubMed ID: 27134074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clonal analyses define the relationships between chromosomal abnormalities and JAK2V617F in patients with Ph-negative myeloproliferative neoplasms.
    Wang X; LeBlanc A; Gruenstein S; Xu M; Mascarenhas J; Panzera B; Wisch N; Parker C; Goldberg JD; Prchal J; Hoffman R; Najfeld V
    Exp Hematol; 2009 Oct; 37(10):1194-200. PubMed ID: 19615425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent der(9;18) in essential thrombocythemia with JAK2 V617F is highly linked to myelofibrosis development.
    Ohyashiki K; Kodama A; Ohyashiki JH
    Cancer Genet Cytogenet; 2008 Oct; 186(1):6-11. PubMed ID: 18786436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
    Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
    Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oligonucleotide array CGH studies in myeloproliferative neoplasms: comparison with JAK2V617F mutational status and conventional chromosome analysis.
    Tefferi A; Sirhan S; Sun Y; Lasho T; Finke CM; Weisberger J; Bale S; Compton J; LeDuc CA; Pardanani A; Thorland EC; Shevchenko Y; Grodman M; Chung WK
    Leuk Res; 2009 May; 33(5):662-4. PubMed ID: 18937974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene.
    Bousquet M; Quelen C; De Mas V; Duchayne E; Roquefeuil B; Delsol G; Laurent G; Dastugue N; Brousset P
    Oncogene; 2005 Nov; 24(48):7248-52. PubMed ID: 16091753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.
    Larsen TS; Christensen JH; Hasselbalch HC; Pallisgaard N
    Br J Haematol; 2007 Mar; 136(5):745-51. PubMed ID: 17313377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations and chromosomal rearrangements of JAK2: not only a myeloid issue.
    Salmoiraghi S; Montalvo ML; D'Agostini E; Amicarelli G; Minnucci G; Spinelli O; Rambaldi A
    Expert Rev Hematol; 2013 Aug; 6(4):429-39. PubMed ID: 23991929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.